Predicting protein refolding from a knowledge of protein interactions under renaturation conditions
Predicting protein refolding from a knowledge of protein interactions under renaturation conditions
批准号:
BB/I016848/1
负责人:
金额:
$11.71万
依托单位:
依托单位国家:
英国
项目类别:
Training Grant
财政年份:
2011
资助国家:
英国
项目状态:
已结题
起止时间:
2011 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Recombinant proteins are often produced as inclusion bodies, which are densely packed aggregates of mis-folded proteins. Isolating the native protein requires dissolving the aggregates under highly denaturing conditions followed by a denaturant removal step to allow for protein refolding. During renaturation, aggregation of partially folded intermediates irreversibly traps inactive proteins. At the industrial level, overcoming this problem requires refolding proteins at low concentrations requiring large tanks. Yields can be improved by using certain additives, which enhance refolding or prevent aggregation. The scaled-up process can only be run in a batch or fed-batch mode, in which protein feed concentration and feed flowrate can be optimized. Often refolding yields can still be low (on the order of 10 percent) and in some instances, proteins do not refold at all, whereas in other cases refolding takes much longer than permitted for a scaled-up process. Thus the overall aims of the proposed project are 1) Understand how solvent influences refolding behaviour so as to make informed decisions about choosing renaturation conditions 2) Provide models of protein aggregation for designing large-scale refolding operations 3) Incorporate knowledge of protein-protein interactions into predictions of protein intrinsic refoldability. 4) Develop robust methods for quantifying refolding yield. Meeting these aims requires determining how refolding yield depends upon protein structural properties and the renaturation conditions (variables including denaturants, salts, additives, pH, protein concentration). We will make this connection by determining the molecular origin of protein intra and intermolecular interactions and then either correlating or fitting the interactions to protein refolding behaviour. The intramolecular interactions will be measured in terms of a protein stability fluoresence assay and an osmotic second virial coefficient (SVC) will be used to characterize the protein-protein interactions. An advantage of our methods is their ability to rapidly screen a range of solvent conditions and proteins. Studies will include therapeutically relevant proteins, which might include recombinant growth colony stimulating factor (rGCSF), human growth hormone (HGH), erythropoietin (EPO), insulin, and insulin like growth factor (ILGF). The protein systems are chosen to encompass a broad range of behaviour so as to isolate structure-interaction relationships. Screening solvent conditions (pH, ionic strength, denaturant concentration, oxidation conditions) will allow us to build up simplified interaction models based upon protein physicochemical properties (protein charge, shape and size, hydrophobicity). This knowledge would then allow us to improve upon current methods for predicting intrinsic refoldability from stability. Also, we will determine how solvent components (denaturants, additives) interact with the protein and/or modulate protein-protein interactions. Understanding the mechanism of interaction will guide the choice of renaturation conditions, with emphasis on finding solvents compatible with the downstream operations. As part of the work we will develop methods for quantifying the refolding yield. The current choice is to use RP-HPLC to separate proteins after the refolding step; natively folded proteins are expected to have different hydrophobicities from incorrectly or aggregated proteins. This method will be assessed in our work by characterizing the monomer peak from the RP-HPLC step using a combination of bioactivity assays, alternative HPLC steps, spectroscopic approaches (FTIR, CD), DSC, and light scattering. For a select few cases, we will also use NMR, which is especially sensitive to any incorrectly folded proteins. The results of the characterization will guide us in choosing a good strategy for assessing refolding yield using a small number of experimentally accessible techniques.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
子宫内膜间质与巨噬细胞之间通过Protein S-MerTK-Apelin信号对
话促进子宫腺肌病蜕膜化缺陷的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:吕海宁
-
依托单位:
有翅与无翅蚜虫差异分泌唾液蛋白Cuticular protein在调控植物细胞壁免疫中的功能
-
批准号:32372636
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:郭慧娟
-
依托单位:
原发性开角型青光眼中SIPA1L1促进小梁网细胞外基质蛋白累积升高眼压的作用机制
-
批准号:82371054
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:郭涛
-
依托单位:
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
-
批准号:82370976
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:郑凌艳
-
依托单位:
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
-
批准号:82370865
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄哲
-
依托单位:
细胞周期蛋白依赖性激酶Cdk1介导卵母细胞第一极体重吸收致三倍体发生的调控机制研究
-
批准号:82371660
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:魏喆
-
依托单位:
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
-
批准号:82371798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:叶俊娜
-
依托单位:
紧密连接蛋白PARD3下调介导黏膜上皮屏障破坏激活STAT3/SNAI2通路促进口腔白斑病形成及进展的机制研究
-
批准号:82370954
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:沈雪敏
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
-
批准号:82371738
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:郑英霞
-
依托单位: